INLB Stock Overview
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States.
+ 1 more risk
Item 9 Labs Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.39|
|52 Week High||US$2.00|
|52 Week Low||US$0.36|
|1 Month Change||-13.89%|
|3 Month Change||-49.01%|
|1 Year Change||-77.07%|
|3 Year Change||-85.54%|
|5 Year Change||n/a|
|Change since IPO||-86.16%|
Recent News & Updates
|INLB||US Pharmaceuticals||US Market|
Return vs Industry: INLB underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: INLB underperformed the US Market which returned -23.2% over the past year.
|INLB Average Weekly Movement||19.1%|
|Pharmaceuticals Industry Average Movement||11.3%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: INLB is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: INLB's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona.
Item 9 Labs Fundamentals Summary
|INLB fundamental statistics|
Is INLB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INLB income statement (TTM)|
|Cost of Revenue||US$15.88m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.23|
|Net Profit Margin||-91.15%|
How did INLB perform over the long term?See historical performance and comparison
Is INLB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INLB?
Other financial metrics that can be useful for relative valuation.
|What is INLB's n/a Ratio?|
Price to Sales Ratio vs Peers
How does INLB's PS Ratio compare to its peers?
|INLB PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
RDHL RedHill Biopharma
ELTP Elite Pharmaceuticals
SHWZ Medicine Man Technologies
INLB Item 9 Labs
Price-To-Sales vs Peers: INLB is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (4.8x).
Price to Earnings Ratio vs Industry
How does INLB's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: INLB is good value based on its Price-To-Sales Ratio (1.5x) compared to the US Pharmaceuticals industry average (2.9x)
Price to Sales Ratio vs Fair Ratio
What is INLB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.5x|
|Fair PS Ratio||4.7x|
Price-To-Sales vs Fair Ratio: INLB is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).
Share Price vs Fair Value
What is the Fair Price of INLB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate INLB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate INLB's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Item 9 Labs forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INLB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INLB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INLB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INLB's revenue (21.2% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: INLB's revenue (21.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INLB's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Item 9 Labs performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INLB is currently unprofitable.
Growing Profit Margin: INLB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INLB is unprofitable, and losses have increased over the past 5 years at a rate of 42.1% per year.
Accelerating Growth: Unable to compare INLB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: INLB has a negative Return on Equity (-27.69%), as it is currently unprofitable.
Discover strong past performing companies
How is Item 9 Labs's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: INLB's short term assets ($5.7M) do not cover its short term liabilities ($39.5M).
Long Term Liabilities: INLB's short term assets ($5.7M) exceed its long term liabilities ($2.6M).
Debt to Equity History and Analysis
Debt Level: INLB's net debt to equity ratio (36.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if INLB's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INLB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: INLB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.9% each year
Discover healthy companies
What is Item 9 Labs's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Item 9 Labs Dividend Yield vs Market|
|Company (Item 9 Labs)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Item 9 Labs)||n/a|
Notable Dividend: Unable to evaluate INLB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INLB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INLB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INLB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INLB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andrew Bowden (34 yo)
Mr. Andrew Douglas Bowden is Chief Executive Officer of Item 9 Labs Corp. since November 18, 2019, Director since September 11, 2018 and serves as its President. Mr. Bowden has extensive experience with mu...
CEO Compensation Analysis
|Andrew Bowden's Compensation vs Item 9 Labs Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||US$722k||US$226k|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||US$589k||US$169k|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||US$12k||US$12k|
Compensation vs Market: Andrew's total compensation ($USD722.31K) is about average for companies of similar size in the US market ($USD781.86K).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
Experienced Management: INLB's management team is considered experienced (3.3 years average tenure).
Experienced Board: INLB's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Item 9 Labs Corp.'s employee growth, exchange listings and data sources
- Name: Item 9 Labs Corp.
- Ticker: INLB
- Exchange: OTCPK
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$36.895m
- Shares outstanding: 95.21m
- Website: https://www.item9labscorp.com
Number of Employees
- Item 9 Labs Corp.
- 2727 North 3rd Street
- Suite 201
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INLB||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Mar 2018|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.